Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets clinical trials

A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed

This study is looking at an HIV medication called Dovato. It's for people aged 50 or older who are already stable on another HIV medicine, Biktarvy. Researchers want to see if switching to Dovato is safe, works well, and is easy to take.